Prosecution Insights
Last updated: April 19, 2026

Nxera Pharma UK Limited

8 pending office actions

Portfolio Summary

8
Total Pending OAs
3
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18556178 GPR35 Agonist Compounds HSU, GRACE CHING 1627 Non-Final OA Oct 19, 2023
18280611 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA MOTEVALLI, OROD 1628 Non-Final OA Sep 06, 2023
18258065 SARS-COV-2 MPRO INHIBITOR COMPOUNDS HAVLIN, ROBERT H 1626 Non-Final OA Jun 16, 2023
18304801 MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM LI, RUIXIANG 1674 Final Rejection Apr 21, 2023
18031416 LINEAR APELIN RECEPTOR AGONISTS COFFA, SERGIO 1658 Non-Final OA Apr 12, 2023
17920583 H4 ANTAGONIST COMPOUNDS MCDOWELL, BRIAN E 1624 Final Rejection Oct 21, 2022
17909907 GLP RECEPTOR AGONISTS BOWLES, DAVID PAUL 1654 Non-Final OA Sep 07, 2022
17107617 METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS PAK, MICHAEL D 1674 Final Rejection Nov 30, 2020

Managing Nxera Pharma UK Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month